Release Date: April 24, 2025
Expiration Date: April 24, 2026
Activity Overview
Over the past decade, the treatment of biliary tract cancers has been fundamentally altered with the introduction of effective targeted and immunologic therapy approaches. Optimal treatment selection now depends on careful evaluation of various molecular alterations that may be present in individual cases.
This podcast features a discussion of the current standard of care in terms of molecular testing and management of biliary tract cancers led by Rohit Gosain, MD; and Rahul Gosain, MD; that features a faculty expert in evaluating and treating cancers.
Target Audience
This educational activity is directed toward US and global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with gastroesophageal adenocarcinoma and biliary tract cancer (BTC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the current standards and limitations of biomarker testing for BTC
- Explore treatment options for patients with advanced, HER2-positive BTC
Rahul Gosain, MD, MBA
Assistant Professor of Clinical Medicine
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Wilmot Cancer Institute – Webster
University of Rochester Medicine
Rochester, NY
Disclosures: Consultancy/advisory: AstraZeneca, Gilead, Janssen Oncology. Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Rohit Gosain, MD
Assistant Professor of Clinical Medicine
University of New York at Buffalo
Director of Roswell Park Care Network Southtowns
Roswell Park Comprehensive Cancer Center
Rochester, NY
Disclosures: Consultancy/advisory: Eisai. Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Ghassan Abou-Alfa, MD, MBA
Professor of Medicine
Weill Cornell Medical College at Cornell University
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED Therapeutics, Servier, Yiviva; Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene Therapeutics, Novartis, Servier, Tango Therapeutics, Tempus, Vector Pharma, Yiviva.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.